Avita Medical (NASDAQ:RCEL – Get Free Report) and Nanovibronix (NASDAQ:FEED – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.
Risk & Volatility
Avita Medical has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500. Comparatively, Nanovibronix has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500.
Insider and Institutional Ownership
27.7% of Avita Medical shares are owned by institutional investors. Comparatively, 16.4% of Nanovibronix shares are owned by institutional investors. 2.2% of Avita Medical shares are owned by insiders. Comparatively, 12.2% of Nanovibronix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Avita Medical | $71.61 million | 4.25 | -$48.59 million | ($1.44) | -6.86 |
| Nanovibronix | $2.55 million | 1.29 | -$18.18 million | ($117.28) | -0.03 |
Nanovibronix has lower revenue, but higher earnings than Avita Medical. Avita Medical is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Avita Medical and Nanovibronix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Avita Medical | -56.96% | N/A | -78.53% |
| Nanovibronix | -1,093.61% | -60.73% | -48.48% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Avita Medical and Nanovibronix, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Avita Medical | 1 | 1 | 5 | 0 | 2.57 |
| Nanovibronix | 1 | 0 | 0 | 0 | 1.00 |
Avita Medical presently has a consensus target price of $11.40, suggesting a potential upside of 15.38%. Given Avita Medical’s stronger consensus rating and higher possible upside, analysts plainly believe Avita Medical is more favorable than Nanovibronix.
Summary
Avita Medical beats Nanovibronix on 10 of the 14 factors compared between the two stocks.
About Avita Medical
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
About Nanovibronix
NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.
Receive News & Ratings for Avita Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avita Medical and related companies with MarketBeat.com's FREE daily email newsletter.
